Document Detail

[VEGF antibodies as therapy for retinopathy of prematurity].
MedLine Citation:
PMID:  20845249     Owner:  NLM     Status:  MEDLINE    
Retinopathy of prematurity (ROP) is one of the three leading causes of legal blindness in childhood in the developed countries. Improved neonatal care has resulted in the increased survival of extremely immature infants at high risk to develop ROP. Current treatment for ROP with laser may prevent blindness by causing involution of pathological vessels and thus inhibit the development of retinal detachment. But this coagulation of the avascular retina is a destructive therapy and does not otherwise ameliorate retinal development. Recent reports have described vascular endothelial growth factor antibodies as therapy for ROP. This article reports our own experience with this new therapy and gives an overview of the recent literature.
I M Oberacher-Velten; H Helbig
Related Documents :
19928699 - Incidence of retinopathy of prematurity in a neonatal intensive care unit in nepal.
18786959 - Retinopathy of prematurity in small-for-gestational age infants compared with those of ...
2225899 - Use of a palatal stabilizing device in prevention of palatal grooves in premature infants.
9727429 - A fiberscopic analysis of velopharyngeal movement before and after primary palatoplasty...
3050829 - Retinopathy of prematurity: progress report.
2478189 - Nasal versus temporal preretinal vasoproliferation in retinopathy of prematurity.
18524739 - Prevalence of vitamin d deficiency among healthy infants and toddlers.
24674979 - Acute drop in blood monocyte count differentiates nec from other causes of feeding into...
8978009 - The use of second-trimester transvaginal sonography to predict placenta previa.
Publication Detail:
Type:  English Abstract; Journal Article; Review     Date:  2010-09-15
Journal Detail:
Title:  Klinische Monatsblätter für Augenheilkunde     Volume:  227     ISSN:  1439-3999     ISO Abbreviation:  Klin Monbl Augenheilkd     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-16     Completed Date:  2011-02-18     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0014133     Medline TA:  Klin Monbl Augenheilkd     Country:  Germany    
Other Details:
Languages:  ger     Pagination:  694-700     Citation Subset:  IM    
Copyright Information:
© Georg Thieme Verlag KG Stuttgart · New York.
Klinik und Poliklinik für Augenheilkunde, Klinikum der Universität Regensburg.
Vernacular Title:
VEGF-Antikörper in der Therapie der Frühgeborenenretinopathie.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / administration & dosage*,  adverse effects
Antibodies, Monoclonal / administration & dosage*,  adverse effects
Antibodies, Monoclonal, Humanized
Combined Modality Therapy
Diseases in Twins / classification,  diagnosis,  drug therapy,  physiopathology
Infant, Extremely Low Birth Weight
Infant, Newborn
Intravitreal Injections
Laser Coagulation
Off-Label Use
Retinopathy of Prematurity / classification,  diagnosis,  drug therapy*,  physiopathology
Vascular Endothelial Growth Factor A / antagonists & inhibitors*,  physiology
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  [Intravitreal drug therapy for retinal vein occlusion--pathophysiological mechanisms and routinely u...
Next Document:  [Anti-VEGF inhibitors and their role in the treatment of diabetic macular oedema].